The Integrated Comprehensive Droplet Digital Detection test can detect bacteria in milliliters of blood. It is different from other diagnostic tools because it “converts blood samples directly into billions of very small droplets,” according to a news release. This minimizes the interference of other components in the blood and makes it easier to directly target bacteria without a purification process.
Additionally, the test is more sensitive than other diagnosis methods, like polymerase chain reaction, which can’t detect low concentrations of bacteria in blood.
“We are extremely excited about this technology because it addresses a long-standing unmet medical need in the field,” Weian Zhao, an assistant professor of pharmaceutical sciences at UCI who led the team, said. “As a platform technology, it may have many applications in detecting extremely low-abundance biomarkers in other areas, such as cancers, HIV and, most notably, Ebola.”
A spinoff from the UCI team, Velox Biosystems, is developing the technology further.
More articles on bloodstream infections:
Sources of bloodstream infections differ in hospital-, community-onset cases
Tennessee dialysis clinic loses license over infection control violations
Study: Antimicrobial lock solutions reduce CLABSI rates by 69%
